Welcome to the latest episode (May 2026) of Diabetes Core Update, where every month Neil Skolnik, MD and John Russell, MD review the most important articles on diabetes, obesity, and cardiometabolic disease.
This month, they discuss:
-
Marston NA, Bohula EA, Bhatia AK, et al. “Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes: Results From the VESALIUS-CV Trial.” JAMA. 2026;335(16):1400–1407. doi:10.1001/jama.2026.3277
-
Lee YJ, Lee SJ, Kim JW, et al. “Intensive LDL Cholesterol Targeting in Atherosclerotic Cardiovascular Disease.” N Engl J Med 2026;394:1365-1375. doi:10.1056/NEJMoa2600283
-
Nissen SE, Wolski K, D’Alessio D, et al. “Cardiorenal Outcomes With Tirzepatide Compared With Dulaglutide in Patients With Diabetes and Cardiovascular Disease: A Post Hoc Analysis of the SURPASS-CVOT Randomized Clinical Trial.” JAMA Cardiol. Published online March 28, 2026. doi:10.1001/jamacardio.2026.0767
-
Moura FA, et al. “Association Between GLP-1 Receptor Agonists and Ischemic Optic Neuropathy: A Meta-analysis.” Diabetes Care. 2026;49(5):724–729. doi.org/10.2337/dc25-1238
-
Ostrominski JW, Ortega-Montiel J, et al. “Comparative Effectiveness of Tirzepatide Versus Dulaglutide or Semaglutide on Major Cardiovascular Events in Type 2 Diabetes and Cardiovascular Disease: Insights From Two Target-Trial Emulations.” Diabetes Care. 2026;49(5):808–817 doi.org/10.2337/dc25-3063
-
Nicole Napoli, “Shingles Vaccine Drastically Cuts Risk of Serious Cardiac Events.” The American College of Cardiology. March 17, 2026 https://www.acc.org/About-ACC/Press-Releases/2026/03/16/19/33/Shingles-Vaccine-Drastically-Cuts-Risk-of-Serious-Cardiac-Events
For information about the American Diabetes Association’s scholarly journals, visit diabetesjournals.org. For more about this podcast, visit About Diabetes Core Update.
Leave a Reply